Effects of statins on cognitive function in patients with Alzheimer's disease in galantamine clinical trials

Drugs and Aging

Volumn 24, Issue 1, 2007, Pages 57-61

  Winblad, Bengt ^a   Jelic, Vesna ^a   Kershaw, Paul ^b   Amatniek, Joan ^c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^c Ortho McNeil Pharmaceutical Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUINDOSTATIN; GALANTAMINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PLACEBO; PRAVASTATIN; SIMVASTATIN;

ABDOMINAL PAIN; AGED; ALZHEIMER DISEASE; ANOREXIA; ARTICLE; BACKACHE; BONE PAIN; CLINICAL TRIAL; COGNITION; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG USE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; LEG CRAMP; LEG PAIN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MUSCLE ATROPHY; MUSCLE WEAKNESS; MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL PAIN; MYALGIA; MYOPATHY; NAUSEA; PRIORITY JOURNAL; RISK FACTOR; VOMITING;

AGED; ALZHEIMER DISEASE; COGNITION DISORDERS; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; GALANTAMINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; NOOTROPIC AGENTS;

EID: 33846461149     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200724010-00004     Document Type: Article

References (22)

1. Kivipelto M, Solomon A, Blennow K, et al., editors. Cholesterol, Alzheimer's disease and statins: proceedings of the 5th Symposium on Aging and Aging Disorders, Stockholm, Sweden, 14-15 April 2005. Acta Neurol Scand Suppl. 2006; 185: 1-120
2. Lutjohann D, von Bergmann K. 24S-hydroxycholesterol: a marker of brain cholesterol metabolism. Pharmacopsychiatry 2003; 36 Suppl. 2: S102-6
3. Vega GL, Weiner MF, Lipton AM, et al. Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease. Arch Neurol 2003; 60: 510-5
4. Refolo LM, Malester B, LaFrancois J, et al. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 2000; 7: 321-31
5. Sparks DL, Kuo YM, Roher A, et al. Alterations of Alzheimer's disease in the cholesterol-fed rabbit, including vascular inflammation: preliminary observations. Ann N Y Acad Sci 2000; 903: 335-44
6. Kivipelto M, Helkala EL, Laakso MP, et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 2001; 322: 1447-51
7. Jick H, Zornberg GL, Jick SS, et al. Statins and the risk of dementia. Lancet 2000; 356: 1627-31
8. Rockwood K, Kirkland S, Hogan DB, et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 2002; 59: 223-7
9. Wolozin B, Kellman W, Ruosseau P, et al. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000; 57: 1439-43
10. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 2002; 360: 1623-30
11. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360: 7-22
12. Eckert GP, Wood WG, Muller WE. Statins: drugs for AD? J Neural Transm 2005; 112: 1057-71
13. Kirsch C, Eckert GP, Koudinov AR, et al. Brain cholesterol, statins and Alzheimer's disease. Pharmacopsychiatry 2003; 36 Suppl. 2: S113-9
14. Crisby M, Carlson LA, Winblad B. Statins in the prevention and treatment of Alzheimer disease. Alzheimer Dis Assoc Disord 2002; 16: 131-6
15. Scott HD, Laake K. Statins for the prevention of Alzheimer's disease. Cochrane Database Syst Rev 2001: CD003160
16. Raskind MA, Peskind ER, Wessel T, et al. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 2000; 54: 2261-8
17. Tariot PN, Solomon PR, Morris JC, et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 2000; 54: 2269-76
18. Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. BMJ 2000; 321: 1445-9
19. Gauthier S. Cholinergic adverse effects of cholinesterase inhibitors in Alzheimer's disease: epidemiology and management. Drugs Aging 2001; 18: 853-62
20. Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999; 341: 498-511
21. Simons M, Schwarzler F, Lutjohann D, et al. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol 2002; 52: 346-50
22. Sjogren M, Gustafsson K, Syversen S, et al. Treatment with simvastatin in patients with Alzheimer's disease lowers both alpha- and beta-cleaved amyloid precursor protein. Dement Geriatr Cogn Disord 2003; 16: 25-30